Press Release

VLP Therapeutics Appoints Louis M. Weiner, M.D., Director of Georgetown Lombardi Comprehensive Cancer Center as Scientific Advisor

2016.03.15|

Gaithersburg, Md.— March 14, 2016 -- VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents

VLP Therapeutics Announces Issuance of U.S. Composition of Matter Patent for i-α Virus Like Particle Platform Technology – Intellectual Property Estate Strengthens Malaria, Dengue and Zika Virus Disease Program –

2016.02.08|

Gaithersburg, Md.—February 8, 2016 -- VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,249,191, Virus Like Particle

VLP Therapeutics to Present at 2015 Dasan Conference

2015.12.02|

VLP Therapeutics, LLC. (“VLP”) announced that its Chief Executive Officer, Dr. Wataru Akahata, was invited to speak at the 2015 Dasan Conference in Busan, Korea on Wednesday, December 2, 2015, at 3:00 p.m. Local Time. The event, which is hosted by the Korean Federation of Science and Technology Societies (KOFST) is titled “the Development of Novel Technology for the Preparedness of Emerging and Unknown Infectious Diseases”and take place at Saintmare, Busan, Korea.

VLP Therapeutics to Present at International Conference on Vaccines R&D 2015

2015.11.02|

VLP Therapeutics, LLC. (“VLP”) announced that its Chief Executive Officer, Dr. Wataru Akahata, will present at the International Conference on Vaccines Research and Development 2015 on Tuesday, November 3, 2015, at 4:00 p.m. Eastern Time. The event will take place at the DoubleTree by Hilton Baltimore-BWI Airport in Linthicum, Maryland.

VLP Therapeutics to Initiate Collaboration with National Cancer Center in Japan

2015.06.04|

VLP Therapeutics, LLC. (“VLP”) announced that it has initiated a research collaboration with the National Cancer Center’s National Cancer Center Research Institute in Japan. The collaboration will help facilitate VLP’s research and development of cancer vaccine candidates.